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Available online 13 February 2016Background: Coffee is one of the most consumed beverages worldwide. In the last years, coffee consumption has
been associated with a number of beneﬁcial effects against metabolic impairment. The aim of this narrative
review was to report the most updated and comprehensive evidence from epidemiological and experimental
studies as well as mechanisms of action of coffee on metabolic impairment.
Methods: A search in electronic databases (PUBMED and EMBASE) was performed to retrieve systematic and
pooled analyses on coffee and diabetes, hypertension, and dyslipidemia. Furthermore, the most accredited
hypotheses and mechanisms of action of coffee have been described.
Results: Coffee consumptionhas been associatedwith reduced risk of diabetes in observational studies. However, the
effect seems not to bemediated by caffeine. Contrasting results have been found in pooled analyses of observational
studies on hypertension, despite short- and long-term follow-ups that have beendemonstrated to inﬂuence the out-
come. Poor or little effect onplasma lipids has been reported in studies on acute administrationof coffee, yet depend-
ing on the typeof coffee preparation. Themainbeneﬁcial effects of coffee consumption seem to rely on the content of
antioxidant and anti-inﬂammatory compounds (i.e., polyphenols). Among themost important, chlorogenic acids
have demonstrated direct anti-hypertensive action through beneﬁcial effect on endothelial function, and signif-
icant improvement in glucose and insulinmetabolism. Also, diterpenes andmelanoidins aremajor candidates as
antioxidant compounds showing the capacity to inhibit the production of inﬂammatory mediators. However,
caffeine and diterpenes may also exert negative effects, such as acute rise in blood pressure and serum lipids.
Conclusion: In light of the most recent evidence, coffee consumption seems to be favorably related with health
and to protect by metabolic impairment.
© 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Metabolic disorders, such as obesity, dysregulated glucose homeo-
stasis, dyslipidemia, and abnormal elevation of systolic and diastolic
blood pressure are important risk factors for cardiovascular disease
(CVD) and are among the major contributors for overall mortality [1].
Overweight and obese population have rapidly increased worldwide
leading to a concomitant rise of type 2 diabetes incidence, especially
in the highest income regions [2]. Hypertension and dyslipidemia affect
20%–40% of the population, showing a signiﬁcant association with ele-
vated BMI, waist circumference, and fasting blood glucose [3]. Altogeth-
er, these conditions represent a major public health issue that could
potentially be reduced by the adoption of a healthier lifestyle. Besides
well-known risk factors, such as sedentary and smoking habits, dietary
habits show a crucial impact towardmetabolic disorders. Several inves-
tigations pointed out the important role of certain dietary patterns, such
as theMediterranean diet or the Dietary Approach to StopHypertension
(DASH), as signiﬁcant protective factors againstmetabolic disorders and
CVD risk factors [4–7]. Cohort studies demonstrated positive effects of
these dietary patterns in both Mediterranean and non-Mediterranean
countries [8,9]. However, their application in non-Mediterranean areas
is somehow limited and some important foods have not been taken
into account when considering such dietary patterns. In the last ten
years, research on coffee drinking has increased dramatically suggesting
that coffee consumption is not as negative as it was hypothesized in
earlier studies [10]. In a recent State-of-the-Art review, a moderate
coffee consumption (2 to 3 cups per day) has shown potential beneﬁts
on cardiometabolic disease, cardiovascular health, and all-causemortal-
ity [11]; although in other studies, high coffee consumption (N4 cups
per day) could have adverse effects [12]. The ﬁndings recently
published pointed out convincing hypotheses on its beneﬁcial effects
in preventing metabolic impairment and laboratory research on its
components provided biological plausibility for its action [13]. In this
narrative review, we report the most important epidemiological evi-
dence on coffee consumption and metabolic impairment, showing the
inconsistency between epidemiological and experimental studies as a
result of the biological differences between short- versus long-time
consumption. Furthermore, the most accredited hypotheses and
mechanisms of action have been described.
2. Epidemiological versus experimental evidence
2.1. Diabetes mellitus, glucose tolerance, and insulin sensitivity
Two recent systematic reviews and meta-analyses analyzing the
speciﬁc association between coffee (data from 28 studies with informa-
tion on 1,109,272 participants) [14], and decaffeinated coffee (10 stud-
ies, 491,485 participants) [15] on incidence of type 2 diabetes found a
nonlinear dose–response relationship between coffee intake and subse-
quent risk of type 2 diabetes, with a decrease of about 8% of risk for
every 1 cup/day increment in coffee intake after adjustment for poten-
tial confounding factors (Table 1). Since similar results were shown
for decaffeinated coffee, it is likely that the protective effect may exist
aside from the inﬂuence of caffeine intake. Another systematic review
including 13 cohort studies with 9473 type 2 diabetes cases and
47,387 participants, found a reduction in type 2 diabetes incidence in
those subjects who consumed 4 or more cups per day compared with
less than 2 cups drinkers [16] (Table 1). Advantage emerged comparing
intake of ﬁltered coffee over pot boiled and decaffeinated coffee over
caffeinated coffee. However, by analyzing single studies reporting in-
conclusive results, a relationwith factors that could explain such results
(i.e., type of coffee or country) could not be found. In addition to the pre-
vious systematic reviews, more recent observational studies are in line
with the hypothesis that coffee intake may be linked to a lower risk of
diabetes [17–21], reduced risk of deterioration of glucose metabolism
[22,23], and insulin resistance [24–27].Generally, results from randomized controlled trials (RCT) exploring
the effect of coffee consumption on glucose metabolism and biological
risk factors for type 2 diabetes widely contrasted those from observa-
tional studies. A recent meta-analysis of RCT in people with type 2 dia-
betes reported substantial negative effect of caffeine intake on blood
glucose control [28] (Table 1). As expected, a major limitation of the tri-
als included in the pooled analysiswas the short period of study. Indeed,
the beneﬁcial effects of caffeinated and decaffeinated instant coffee on
glucose metabolism were found in a recent study that lasted 16 weeks
[29], but studies exploring the acute effects following themeal reported
opposite or inconclusive results. An experimental study conducted on
healthy volunteers resulted in an increasing insulin response and de-
creased insulin sensitivity index after a 75 g oral glucose tolerance
test, compared to water [30]. While in another RTC on healthy subjects,
coffee consumption increased glucose concentration and lowered insu-
lin concentrations in the ﬁrst 30 min after a standardized meal [31].
Caffeinated coffee, after either a high or low glycemic indexmeal, signif-
icantly impaired acute blood glucose management and insulin insensi-
tivity compared with ingestion of decaffeinated coffee [32,33], despite
these effects being stronger after a lipid-richmeal [34]. Moreover, coffee
consumption during a carbohydrate meal seems to decrease the insulin
sensitivity of a second carbohydrate meal, even without an additional
coffee intake [35]. Some other experimental studies reported poorly sig-
niﬁcant results of caffeinated coffee on postprandial glycemic tolerance
and insulin sensitivity [36,37] or increase of coffee-derived compounds
but no changes of markers of glucose metabolism at an oral glucose
tolerance test were found [38].
2.2. Hypertension
Epidemiological studies exploring the role of coffee consumption on
the development of hypertension showed inconclusive results. Among
the several pooled analysis that have been conducted during last
10 years, the most recent meta-analysis of epidemiological studies, in-
cluding 6 prospective cohorts with a total of 172,567 participants and
37,135 incident cases of hypertension, concluded that the summary rel-
ative risks (RRs) for hypertension was 1.09 (95% conﬁdence interval
(CI): 1.01, 1.18) for consumption of 1–3 cups per day,whereas no signif-
icant risk was found for higher categories (N3 cups/day) [39] (Table 1).
A meta-analysis of experimental and observational epidemiological
studies on coffee consumption and hypertension reported low-quality
evidence, unable to showany statistically signiﬁcant effect of coffee con-
sumption on blood pressure or the risk of hypertension [40] (Table 1).
Another meta-analysis investigating the role of coffee/caffeine intake
in hypertensive subjects results in an acute increment of BP for ≥3,with-
out any long-term association between coffee intake and BP [41]
(Table 1). These ﬁndings seem to conﬁrm the results of a previous
meta-analysis of RCT conducted with regard to the intake of both
coffee and caffeine [42] (Table 1). They reported a signiﬁcant rise of
2.04 mmHg (95% CI: 1.10, 2.99) in systolic blood pressure and
0.73 mmHg (95% CI: 0.14, 1.31) in diastolic blood pressure for pooled
analysis of coffee and caffeine trials. When coffee trials and caffeine tri-
als were analyzed separately, blood pressure elevations appeared to be
signiﬁcant only for caffeine but not for coffee, suggesting that despite
the biochemical mechanism of action of caffeine supporting the biolog-
ical plausibility that acute ingestion of such compounds may increase
blood pressure, when ingested through coffee, the blood pressure effect
of caffeine was somehow attenuated. It is noteworthy that most recent
investigations found a signiﬁcantly reduced risk of hypertension evalu-
ated in both cross-sectional and prospective design only when analysis
was stratiﬁed by smoking status [43,44].
2.3. Dyslipidemia and lipid metabolism
The early epidemiological studies published in the 1980s demon-
strated a signiﬁcant association between coffee consumption and
Table 1
Characteristics of meta-analysis and systematic review included in this review.
Author Year
Number and
design of the
studies
Participants Cases Outcome Exposure Main results and RR (95% CI)
Diabetes mellitus, glucose tolerance, and insulin sensitivity
Ding et al. [14] 2014 28 PCS 1,109,272 43,335 T2DM incidence
0 coffee cup/d 1
1 coffee cups/d 0.92 (0.90, 0.94)
2 coffee cups/d 0.85 (0.82, 0.88)
3 coffee cups/d 0.79 (0.75, 0.83)
4 coffee cups/d 0.75 (0.71, 0.80)
5 coffee cups/d 0.71 (0.65, 0.79)
6 coffee cups/d 0.67 (0.61, 0.74)
Jiang et al. [15] 2014
26 PCS 1,096,647 50,595 T2DM incidence Coffee lowest vs highest 0.71 (0.67, 0.76)
10 PCS 491,485 29,165 T2DM incidence
Decaffeinated coffee
lowest vs highest
0.79 (0.69, 0.91)
6 PCS 321,960 9302 T2DM incidence
Caffeine, lowest Vs
highest
0.70 (0.65, 0.75)
Whitehead et al. [28] 2013
2 RCTs
53 T1DM
individuals
N/A Hypoglycemic episodes Caffeine 400–500 mg
Increased awareness and decreased
duration of hypoglycemic episodes
6 RCTs
73 T2DM
individuals
N/A
Blood glucose and
insulin sensitivity
Caffeine 200–500 mg
Increased blood glucose (16%–28%) and
insulin levels (19%–48%). Decreased
insulin sensitivity by 14%–37%.
1 RCT 8 GDM individuals N/A
Blood glucose and
insulin sensitivity
Caffeine 200 mg
Increased blood glucose (19%) and
insulin level (29%) and reduced insulin
sensitivity by 18%.
Muley et al. [16] 2012 13 PCS 12,47,387 9473 T2DM incidence Coffee
T2DM incidence was reduced in subjects
who drank 4–6 cups/d and 6–7 cups/d
compared with b2 cups/d drinkers
Hypertension
Mesas et al. [41] 2011
5 RCTs
85 hypertensive
individuals
N/A Acute effect on BP Caffeine 200–300 mg)
SBP 8.14 mmHg (5.68, 10.61) DBP 5.7
mmHg (4.1, 7.4)
6 RCTs
364 hypertensive
individuals
N/A Long-term effect on BP Coffee or caffeine No change in BP
Zhang et al. [39] 2011 6 PCS 172,567 37,135 Hypertension incidence
b1 coffee cup/d 1
1–3 coffee cups/d 1.09 (1.01, 1.18)
3–5 coffee cups/d 1.07 (0.96, 1.20)
N5 coffee cups/d 1.08 (0.96 ,1.21)
Noordzija et al. [42] 2005 16 RTCs 110 N/A BP
Coffee
SBP 1.22 mmHg (0.52, 1.92)
DBP 0.49 mmHg (−0.06, 1.04)
Caffeine
SBP 4.16 mmHg (2.13, 6.20)
DBP 2.41 mmHg (0.98, 3.84)
Caffeine and coffee
SBP 2.04 mmHg (1.10, 2.99)
DBP 0.73 mmHg (0.14, 1.31)
Dyslipidemia and lipid metabolism
Cai et al. [54] 2012 12 RCT 1017 N/A Serum lipids
Coffee 2.4 to 8.0
cups/day
TC 8.05 mg/dl (4.48,11.62)
LDL-C 5.44 mg/dl (1.38,9.51)
HDL-C -0.12 mg/dl (−0.62, 0.38)
TG 12.55 mg/dl (3.47, 21.64)
CI, conﬁdence interval; BP, blood pressure; DBP, diastolic blood pressure; GDM, gestational diabetes mellitus; HDL, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; N/A, not applicable; PCS, prospective cohort study; RTC, randomized controlled trial; SBP, systolic blood pressure; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes
mellitus; TC, total cholesterol; TG, triglyceride.
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effect of coffee has been demonstrated to depend on the diterpenes
cafestol and kahweol, and by themethod of brewing [49]. Contrarily,ﬁl-
tered coffee consumption seems to have poor or no association with
serum lipid levels compared to boiled coffee, maybe due to the reten-
tion of diterpenes by the paper ﬁlter [50]. Thus, results from epidemio-
logical studies reported contrasting results with strong country-speciﬁc
characteristics due to the different bioactive compounds contained in
coffee in different countries and type of preparation method used
[51–53].
Contrasting with observational studies, a recent meta-analysis of
RCT evaluated the effects of coffee intake on serum lipids in 12 studies
conducted on 1017 subjects [54] (Table 1). On average, drinking coffee
for 45 days was associated with an increase of 8.1 mg/dl (95% CI: 4.5,
11.6) for total cholesterol, 5.4 mg/dl (95% CI: 1.4, 9.5) for LDL-C, and
12.6 mg/dl (95% CI: 3.5, 12.6) for triglycerides. Meta-regression analysis
also revealed a positive dose–response relation between coffee intake
and total cholesterol, LDL-C, and triglycerides. However, other more re-
cent studies (thus not included in the previous meta-analysis) reportedpoor or little inﬂuence on plasma lipids following acute ingestion of
coffee [55] or even a suppression of postprandial hyperlipidemia
[56], signiﬁcant decrease of triglycerides, and increase of HDL-
cholesterol [55].
3. Potential beneﬁcial mechanisms of action
3.1. Glucose and insulin metabolism regulation
Despite the acute ingestion of caffeine resulting in a reduction of in-
sulin sensitivity due to decreased glucose storage [57,58], this short-
term effect cannot be observed after long-time consumption of coffee
because of an overall impairment of effects of caffeine after continued
intake [59]. Coffee has been reported to be the main contributor of a
number of antioxidant compounds, including some polyphenols such
as chlorogenic acids [60]. This family of polyphenols (mostly caffeic
and ferulic acid) demonstrated the ability to affect some metabolic
pathways [61,62]. In animal models, consumption of chlorogenic acids
reduced fasting plasma glucose [63–65], increased sensitivity to insulin
4 S. Buscemi et al. / NFS Journal 3 (2016) 1–7[66], and slowed the appearance of glucose in circulation after glucose
load [67,68]. This particular family of molecules showed a speciﬁc com-
petitive inhibition of the glucose-6-phosphate translocase in rat liver
microsomes [69] an enzyme highly involved in the regulation of ho-
meostasis and blood glucose levels. At the cellular level, chlorogenic
acids activate adenosine monophosphate-activated protein kinase
(AMPK), a sensor and regulator of cellular energy balance, leading to
beneﬁcial metabolic effects, such as the inhibition of fatty acid synthesis
and hepatic glucose production. Thus, chlorogenic acid by the activation
of AMPK may contribute to lipid and glucose metabolism regulation
[70]. Further hypotheses on themechanism through which chlorogenic
acids may prevent diabetes consist in their capacity to reduce sodium-
dependent glucose transport in brush bordermembrane vesicles isolat-
ed from rat small intestine [71], and to inhibitα-amylase [72,73] andα-
glucosidase activity [74,75], two key enzymes responsible for digestion
of dietary carbohydrates, resulting in a reduction of intestinal absorp-
tion of glucose.
Together with phenolic compounds, trigonelline and sex hormone-
binding globulin (SHBG) also demonstrated a protective effect against
diabetes [67,76]. The vitamin B3 precursor trigonelline has been
shown to potentially improve insulin sensitivity in animal studies
by inhibiting dipeptidylpeptidase-4 and α-glucosidase activities in
both plasma and small intestine [77] and ameliorating the oxidative
stress in type 2 diabetic rats downregulating the gene expressions
involved with NADPH oxidase and mitochondrial electron transfer
system [78]. SHBG have been related with type 2 diabetes since
membranes of a variety of cells are able to speciﬁcally bind them with
high afﬁnity, and SHBG mediates the steroid-signaling system at the
cell membrane through the SHBG receptors and exerting direct meta-
bolic effects [79].
3.2. Lipid metabolism regulation
It has been reported that some components present in unﬁltered
coffee (i.e., cafestol and kahweol) raise serum lipids, but a clear involve-
ment in the deposition of LDL-C and/or an oxidation of this lipid fraction
has not been demonstrated. Accordingly, it is still debatable if coffee
consumption can affect lipid metabolism in order to signiﬁcantly in-
crease cardiovascular risk [80]. On the contrary, it has been reported
that coffee intake increase LDL-C resistance to oxidative modiﬁcations
probably as a result of the incorporation of the phenolic acids in coffee
into the cells [81]. An experimental study evaluating the effects of
chlorogenic acids on lipid metabolism in diabetic rats found a signif-
icant increase in the concentrations of plasma and tissue (liver and
kidney) lipids, cholesterol, triglycerides, free fatty acids and phos-
pholipids, and LDL and very low-density lipoproteins, respectively,
and a decrease in the concentration of HDL [82]. It was demonstrated
that their action depended on the capacity to increase the activity of
3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase in
the liver and kidney and a decrease in the activities of lipoprotein li-
pase (LPL) and lecithin cholesterol acyl transferase (LCAT) in the
plasma [82].
A number of epidemiological studies reported a positive association
between coffee consumption and adiponectin levels, an insulin-
sensitive hormone playing a central role in glucose and lipid metabo-
lism, both in healthy individuals [83–86] and in those with metabolic
syndrome-relateddisorders [87,88]. These studies remarked the inverse
association between coffee consumption and obesity or visceral fat area.
Experimental studies reported that coffeemay play a role in the expres-
sion of adipo-R2 gene, which activate its downstream signaling
pathways mainly by activating AMPK and peroxisome proliferator-
activated receptors alpha (PPAR-a) [89]. Coffee polyphenols and
melanoidins protected the liver from damage caused by a hypercaloric
diet in an animal model, and this protection was partially mediated by
a reduction in liver inﬂammation, through increases of adipo-R2 gene
and anti-inﬂammatory cytokines IL-4 and IL-10 [90].3.3. Effects on blood pressure
Despite caffeine inhibiting phosphodiesterase non-selectively,
thereby causing an accumulation of cAMP, which can mediate a vaso-
constrictive response [91], experimental studies reported that an
acute increase in blood pressure due to coffee intake develops with
rapid tolerance [92,93] and that intravenous caffeine is responsible for
the increase in muscle sympathetic activity and blood pressure in both
habitual and non-habitual coffee drinkers, but coffee intake led to in-
creased blood pressure only in non-habitual coffee drinkers [94]. Sever-
al components of coffee demonstrate anti-hypertensive action [95].
Chlorogenic acids are hypothesized to exert anti-hypertensive effects
by increasing nitric oxide bioavailability and improving endothelial
function,which lead to a reduction of blood pressure [96]. Experimental
studies also demonstrated that the depletion in roasted coffee of
hydroxyhydroquinone, a particular fraction of chlorogenic acid, en-
hanced the anti-hypertensive effects of chlorogenic acids in a marginal-
ly dose-dependent manner [97]. Moreover, coffee is also rich in blood
pressure-lowering minerals (i.e., potassium and magnesium) that may
contribute to its effect on blood pressure [98].
3.4. Antioxidant activity
Oxidative stress is heavily involved inmetabolism impairment path-
ways, aswell as in the development of chronic subclinical inﬂammation
that contribute to chronic disease incidence and progression. The in-
ﬂammatory response could be mediated by many factors, such as the
main phenolic compounds of coffee [99]. In particular, chlorogenic
acids demonstrated strong antioxidant effect in a dose–response rela-
tionship as a results of the inhibition of the production of inﬂammatory
mediators [100–102], by inhibiting protein tyrosine phosphatase 1B
[103] and depressing the expression of pro-inﬂammatory cytokine
genes [104,105]. These compounds also demonstrated decreased endo-
thelial dysfunction [106] by modulating inﬂammatory NF-κB activation
via the redox-related c-Src/ERK andNIK/IKK pathways via the reduction
of oxidative stress [107]. Diterpenes are multitasking molecules that
play a role in the regulation of angiogenesis and inﬂammation processes
[108,109]. Themost studied effects of cafestol regard its capacity to reg-
ulate pathological angiogenesis [108]. Kahweol has demonstrated
antioxidant properties by inhibiting both cyclo-oxigenase-2 (COX-2)
expression andmonocyte chemoattractant protein-1 (MCP-1) secretion
in endothelial cells, key proteins mediating inﬂammatory processes
[109]. It has been reported that cafestol and kahweol regulate Sp1
target proteins, which are involved in various biological processes
such as differentiation, metabolism, cell growth, angiogenesis, and apo-
ptosis [110]. Melanoidins, compounds formed during the roasting of
coffee beans, have demonstrated strong antioxidant activity and to sig-
niﬁcantly inhibit lipid oxidation [111,112]. In an animal model of
steatohepatitis, melanoidins protected liver from damage caused by a
high-fat diet by a reduction in hepatic fat accumulation (through in-
creased fatty acid β-oxidation), systemic and liver oxidative stress
(through the glutathione system), liver inﬂammation (throughmodula-
tion of genes), and expression and concentrations of proteins and
cytokines related to inﬂammation [90]. Finally, caffeine itself and its
metabolites theobromine and xanthine, have been reported to possess
antioxidant properties, such as DNA-protection through quenching of
hydroxyl radical generating systems [113].
4. Controversial effects and future prospective
Besides the potential beneﬁcial effects of coffee consumption, great
attention should be paid in order to explain its negative effects on
human health. It has been often reported a U-shaped effect of coffee
on several health outcomes [42,114,115], suggesting that a detrimental
effect may occur at higher quantities of consumption. Moreover, results
from epidemiological and experimental studies are rarely univocal, but
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ological studies provide insight into the long-term effects of coffee
consumption but observational evidence cannot demonstrate causal
relationship. Moreover, cross-sectional studies may have a lack of reli-
ability due to the phenomenon of “reverse causation”, namely, an adap-
tation of coffee consumption after developing the disease. Prospective
cohort studies should minimize such phenomenon, but control over
time of coffee consumption may results difﬁcult and the time distance
between the exposure assessment (i.e., coffee intake at baseline) and
the outcome evaluation may bias results. Thus, evidence from epidemi-
ological studies is only in part demonstrated in the experimental set-
ting, and potential confounders (i.e., cigarette smoking) may affect
ﬁndings. The randomization process of RCT should, at least in part, at-
tenuate the effects of confounders theoretically equally distributed
over both intervention and control groups. However, compared to epi-
demiological studies, RCT are usually conducted over a limited period
of time. Moreover, the effects follow generally a ﬁxed dose of coffee
(or caffeine) and controlled in a predetermined moment, thus estimat-
ing mostly acute effects of coffee and often not corresponding to “real-
world” coffee drinking. Finally, regarding experimental studies, most
of the data existing is based on in vitro and animal studies, therefore
the relevance of ﬁndings for the application in humans is still unclear.
5. Conclusion
In conclusion, in light of themost recent epidemiological and exper-
imental evidence, coffee consumption seems to be favorably related
with health and to protect bymetabolic impairment. Despite themech-
anisms of action being not completely understood, its content in poly-
phenols and antioxidant compounds may be countering many of the
negative effects reported in the early researches. Moreover, compo-
nents with demonstrated harmful effects (i.e., caffeine and diterpenes)
are nowadays also being reconsidered due to novel discoveries of new
potential positive effects or new hypotheses on their interaction with
metabolism regulation.
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